<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - BOTULINUM TOXIN TYPE A</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>BOTULINUM TOXIN TYPE A</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of focal spasticity (including hand and wrist disability associated with stroke) (specialist use only)</span>,
                <span class="indication">Blepharospasm (specialist use only)</span>,
                <span class="indication">Hemifacial spasm (specialist use only)</span>,
                <span class="indication">Spasmodic torticollis (specialist use only)</span>,
                <span class="indication">Severe hyperhidrosis of the axillae (specialist use only)</span>,
                <span class="indication">Prophylaxis of headaches in adults with chronic migraine (specialist use only)</span>,
                <span class="indication">Temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years (specialist use only)</span>,
                <span class="indication">Ankle disability due to lower limb spasticity associated with stroke (specialist use only)</span>,
                <span class="indication">Management of bladder dysfunctions (specialist use only)</span>,
                <span class="indication">Temporary improvement of moderate to severe crow's feet (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intradermal injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>
            <b>Important</b>: information is specific to each individual preparation.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid unless essential&#8212;toxicity in <i>animal</i> studies (manufacturer of <i>Botox</i>
            <tm tmtype="reg"/> advise avoid).</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Acute urinary retention (specific to use in bladder disorders only)</li>
            <li>catheterisation difficulties (specific to use in bladder disorders only)</li>
            <li>generalised disorders of muscle activity</li>
            <li>infection at injection site</li>
            <li>myasthenia gravis</li>
            <li>presence of bladder calculi (specific to use in bladder disorders only)</li>
            <li>urinary tract infection (specific to use in bladder disorders only)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Excessive doses may paralyse distant muscles, increased electrophysiologic jitter in some distant muscles, influenza-like symptoms, misplaced injections may paralyse nearby muscle groups,
              </p>
              <p>
                <strong>rare:</strong> Antibody formation (substantial deterioration in response), arrhythmias, myocardial infarction, seizures,
              </p>
              <p>
                <strong>veryRare:</strong> Aspiration, dysphagia, dysphonia, exaggerated muscle weakness, respiratory disorders,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abnormal skin odour, alopecia, hot flushes, non-axillary sweating, paraesthesia, pruritus, subcutaneous nodule, dry eye, ecchymosis, facial oedema, irritation, keratitis, lacrimation, lagophthalmos, photophobia, ptosis, dysphagia, hypertonia, purpura, dry eye, ecchymosis, facial oedema, irritation, keratitis, lacrimation, lagophthalmos, photophobia, ptosis, back pain, dizziness, drowsiness, dry mouth, dysphagia and pooling of saliva (occurs most frequently after injection into sternomastoid muscle), headache, hypertonia, malaise, nausea, numbness, rhinitis, stiffness, weakness, facial oedema, headache, ptosis, pain in extremities,
              </p>
              <p>
                <strong>uncommon:</strong> joint pain, myalgia, conjunctivitis, dermatitis, diplopia, dizziness, drooping, dry mouth, ectropion, entropion, facial weakness, headache, paraesthesia, tiredness, visual disturbances, amnesia, arthralgia, bursitis, cough, depression, dry mouth, dysaesthesia, haematoma, headache, insomnia, malaise, pain in extremities, paraesthesia, peripheral oedema, vertigo, nausea, conjunctivitis, dermatitis, diplopia, dizziness, drooping, dry mouth, ectropion, entropion, facial weakness, headache, paraesthesia, tiredness, visual disturbances, colitis, diarrhoea, diplopia, dyspnoea, eye pain, myalgia, ptosis, skeletal pain, sweating, tremor, voice alteration, vomiting, anxiety, asthenia, blepharitis, dizziness, dry mouth, dry skin, muscle cramp, nausea, paraesthesia, photosensitivity reactions, tinnitus, visual disturbances,
              </p>
              <p>
                <strong>rare:</strong> eyelid bruising and swelling (minimised by applying gentle pressure at injection site immediately after injection), eyelid bruising and swelling (minimised by applying gentle pressure at injection site immediately after injection),
              </p>
              <p>
                <strong>veryRare:</strong> angle-closure glaucoma, corneal epithelial defect, corneal perforation, corneal ulceration, angle-closure glaucoma, corneal epithelial defect, corneal perforation, corneal ulceration,
              </p>
              <p>
                <strong>notKnown:</strong> arthralgia, peripheral oedema, rash,
              </p>
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients and carers should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties; they should be advised to seek immediate medical attention if swallowing, speech or breathing difficulties occur.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA260</h3>
              <p outputclass="title">Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (June 2012)</p> <p>Botulinum toxin type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine, (defined as headaches on at least 15 days per month, of which at least 8 days are with migraine), that has not responded to at least three prior pharmacological prophylaxis therapies and whose condition is appropriately managed for medication overuse.</p><xref format="html" href="http://www.nice.org.uk/TA260">www.nice.org.uk/TA260</xref>
                <a href="http://www.nice.org.uk/TA260" target="_blank">www.nice.org.uk/TA260</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Atrophy in target muscle
          </li>
          <li>
            chronic respiratory disorder
          </li>
          <li>
            elderly
          </li>
          <li>
            excessive weakness in target muscle
          </li>
          <li>
            history of aspiration
          </li>
          <li>
            history of dysphagia
          </li>
          <li>
            inflammation in target muscle
          </li>
          <li>
            neurological disorders
          </li>
          <li>
            neuromuscular disorders
          </li>
          <li>
            off-label use (fatal adverse events reported)
          </li>
        </ul>
        <ul>
          <li>
              <strong>When used for blepharospasm or hemifacial spasm:</strong>
            risk of angle-closure glaucoma
          </li>
        </ul>
        <ul>
          <li>
            <p>When used for blepharospasm and hemifacial spasm, reduced blinking can lead to corneal exposure, persistent epithelial defect and corneal ulceration (especially in those with VIIth nerve disorders)&#8212;careful testing of corneal sensation in previously operated eyes, avoidance of injection in lower lid area to avoid ectropion, and vigorous treatment of epithelial defect needed.</p>
          </li>
          <li>
            <p>Neuromuscular or neurological disorders can lead to increased sensitivity and exaggerated muscle weakness including dysphagia and respiratory compromise.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Avoid in women of child-bearing age unless using effective contraception.</p>
            </section>
      </section>



      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Preparations are not interchangeable.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of BOTULINUM TOXIN TYPE A</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76759"><a href="../medicinalForm/PHP76759.html" data-target="#PHP76759" data-action="load">Powder for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
